bioAffinity stockholders approve 15x equity plan expansion and authorize reverse stock split

Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read

Key Changes

• high

  Stockholders approved expanding the 2024 Equity Incentive Plan from 66,666 to 1,000,000 shares, a 15-fold increase that significantly expands management's ability to grant stock-based compensation and will dilute existing shareholders when awards are issued.

  Item 5.07 verify on EDGAR →
• high

  Authorized reverse stock split at ratio between 1-for-2 and 1-for-250, with exact ratio at board's discretion. Typically used to maintain exchange listing requirements by boosting per-share price while reducing share count.

  Item 5.07 verify on EDGAR →
• high

  Approved issuance of up to 637,120 shares from warrant exercises and anti-dilution adjustments tied to August 2025 financing and Series B Preferred stock, representing substantial potential dilution from existing instruments.

  Item 5.07 verify on EDGAR →